Ambarella Announces First Quarter Fiscal Year 2025 Earnings Conference Call to be Held May 30, 2024
10 mai 2024 20h00 HE
|
Ambarella
SANTA CLARA, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its first quarter fiscal year 2025 earnings...
Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
10 mai 2024 12h36 HE
|
Merus N.V.
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ;...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
10 mai 2024 07h00 HE
|
Akero Therapeutics Inc.
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and...
Kronos Bio Reports First-Quarter 2024 Financial Results
09 mai 2024 16h05 HE
|
Kronos Bio, Inc.
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new...
One Stop Systems Reports Q1 2024 Results
09 mai 2024 16h04 HE
|
One Stop Systems, Inc.
ESCONDIDO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. ("OSS" or the "Company") (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI),...
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
09 mai 2024 16h01 HE
|
Iovance Biotherapeutics, Inc.
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment...
Critical Response Group Partners with McCarthy Capital to Accelerate Growth
09 mai 2024 11h01 HE
|
Critical Response Group
Critical Response Group Partners with McCarthy Capital to Accelerate Growth
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
09 mai 2024 08h00 HE
|
Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
09 mai 2024 08h00 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory...
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
09 mai 2024 07h30 HE
|
XOMA Corporation
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...